CLARET ASSET MANAGEMENT Corp lifted its stake in CRH Medical Corp (NYSEAMERICAN:CRHM) by 587.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 163,516 shares of the company’s stock after buying an additional 139,716 shares during the period. CLARET ASSET MANAGEMENT Corp owned approximately 0.23% of CRH Medical worth $503,000 as of its most recent filing with the Securities and Exchange Commission.

Separately, Renaissance Technologies LLC lifted its stake in CRH Medical by 3.5% during the second quarter. Renaissance Technologies LLC now owns 669,700 shares of the company’s stock worth $2,029,000 after purchasing an additional 22,500 shares during the last quarter.

NYSEAMERICAN CRHM opened at $3.05 on Friday. CRH Medical Corp has a twelve month low of $2.51 and a twelve month high of $3.79.

CRH Medical (NYSEAMERICAN:CRHM) last posted its quarterly earnings data on Wednesday, July 31st. The company reported $0.02 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.01 by $0.01. The company had revenue of $30.48 million during the quarter, compared to analyst estimates of $29.50 million.

In related news, President James Kreger sold 10,000 shares of the stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $3.24, for a total value of $32,400.00. Following the completion of the sale, the president now directly owns 51,000 shares in the company, valued at $165,240. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Several research firms have weighed in on CRHM. Bloom Burton upgraded CRH Medical from an “accumulate” rating to a “buy” rating in a research note on Thursday, August 1st. Zacks Investment Research upgraded CRH Medical from a “sell” rating to a “hold” rating in a research note on Monday, August 19th. One investment analyst has rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $3.25.

CRH Medical Profile

CRH Medical Corporation provides various products and services to gastroenterologists in the United States and Canada. It offers CRH O'Regan system, a single use, disposable, and hemorrhoid banding technology for treating various grades of hemorrhoid. The company also offers anesthesia services for patients undergoing endoscopic procedures.

Recommended Story: Are sell-side analysts objective?

Want to see what other hedge funds are holding CRHM? Visit to get the latest 13F filings and insider trades for CRH Medical Corp (NYSEAMERICAN:CRHM).

Institutional Ownership by Quarter for CRH Medical (NYSEAMERICAN:CRHM)

Receive News & Ratings for CRH Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRH Medical and related companies with's FREE daily email newsletter.